AlphaCentric Advisors
AlphaCentric Advisors reported 259 stocks worth $118M in its 13F filing for Q2 2026, filed Jul 24, 2026. Its largest holdings are GILD (2.2%), VRTX (2.1%) and INVH (1.9%). Compared with Q1 2026, the fund opened new positions in QQQ, QQQM and ASND, added to GILD, VRTX and AZN, trimmed EEFT, IWD and RPV and sold out of ASND, RZLV and BBAI.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 5 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  GILD Gilead Sciences Inc | $2.6M | 2.2% | 20K | +166 (+1%) | 5 of 5 | |
| 2 |  VRTX Vertex Pharmaceuticals I | $2.5M | 2.1% | 5,002 | +71 (+1%) | 4 of 5 | |
| 3 |  INVH Invitation Homes Inc | $2.2M | 1.9% | 73K | No change | 3 of 5 | |
| 4 |  AZN Astrazeneca PLC Ord | $2.2M | 1.8% | 11K | +162 (+1%) | 2 of 5 | |
| 5 |  ROIV Roivant Sciences Ltd | $1.7M | 1.4% | 48K | +688 (+1%) | 4 of 5 | |
| 6 |  ARGX Argenx SE | $1.7M | 1.4% | 1,806 | +12 (+1%) | 4 of 5 | |
| 7 |  NBIX Neurocrine Biosciences Inc | $1.6M | 1.4% | 9,727 | +120 (+1%) | 5 of 5 | |
| 8 |  INCY Incyte Corp | $1.6M | 1.4% | 14K | +206 (+1%) | 3 of 5 | |
| 9 |  AXSM Axsome Therapeutics Inc | $1.6M | 1.4% | 6,531 | +93 (+1%) | 4 of 5 | |
| 10 | APOGEE THERAPEUTICS INC | $1.5M | 1.3% | 12K | +164 (+1%) | 5 of 5 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 ASND Ascendis Pharma A/s | $1M | 4,526 |
BRAEMAR HOTELS & RESORTS INC | $985K | 1M |
WHITESTONE REIT | $460K | 28K |
 RZLV Rezolve AI PLC | $384K | 150K |
 BBAI Bigbear AI Hldgs Inc | $264K | 75K |
🔒 Free account: see all 28.
Reported value
last 5 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Jul 24, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →AlphaCentric Advisors 13F FAQ
What does AlphaCentric Advisors own?
AlphaCentric Advisors reported 259 stocks worth $118M in its 13F filing for Q2 2026, filed Jul 24, 2026. Its largest holdings are GILD (2.2%), VRTX (2.1%) and INVH (1.9%). The table above lists every position in the filing (the top 10 without an account).
What did AlphaCentric Advisors buy and sell in Q2 2026?
Compared with Q1 2026: 35 new positions, 174 added to, 36 trimmed and 28 sold out. New positions include QQQ, QQQM and ASND. It sold all of ASND, RZLV and BBAI.
When will AlphaCentric Advisors file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is AlphaCentric Advisors's portfolio worth?
The Q2 2026 filing reports $118M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.